Sosei Group (JP:4565) has released an update.
Nxera Pharma, previously Sosei Group, has announced a new partnership with Shionogi for the distribution and sales of QUVIVIQ™, a novel insomnia treatment in Japan, following the termination of a prior agreement with Mochida Pharmaceutical. Shionogi will now handle all sales and distribution activities in Japan, while Nxera will supply the drug and Mochida will continue to manufacture it. Chris Cargill, CEO of Nxera, believes QUVIVIQ™ will be a major product in addressing the widespread issue of insomnia in Japan.
For further insights into JP:4565 stock, check out TipRanks’ Stock Analysis page.
